|
Bethesda, MD Scientists in Tokyo have discovered
a new protein, named PICT-1, that is involved in regulating PTEN, the
second most commonly mutated tumor suppressor in human tumors. This
discovery suggests the possibility of a new tumorigenic pathway that
is due to defects in a protein involved in stabilizing PTEN rather
than defects in PTEN itself.
The research appears as the "Paper of the Week" in
the October 29 issue of the Journal of Biological Chemistry, an
American Society for Biochemistry and Molecular Biology journal.
Mutations in the PTEN tumor suppressor are found in
a variety of human cancers including breast and prostate cancers.
Approximately 20 percent of the mutations are located in a segment of
70 amino acids at the C-terminus of PTEN. These mutations lead to the
rapid degradation of PTEN in cells, indicating that this region is
critical for ensuring PTEN stability.
Studies have shown that cells add phosphate
molecules to specific serine and threonine residues within the
C-terminal segment to stabilize PTEN. Curious about the proteins
involved in this stabilization, Dr. Tomohiko Maehama and his
colleagues at the Tokyo Metropolitan Institute of Medical Science and
the Tokyo Metropolitan University screened a library of human brain
cDNA to find proteins that interact with PTEN. They identified a new
protein that binds to the C-terminus of PTEN and named it PICT-1 (protein
interacting with the carboxyl terminus 1).
Maehama and his colleagues discovered that PTEN
molecules with mutations in their C-terminus are unable to bind to
PICT-1, and that PICT-1 stabilizes PTEN by regulating the
phosphorylation of a serine in the C-terminal segment. "From
scientific point of view, it should be noted that PICT-1 is the first
protein that interacts with the PTEN protein and regulates its
phosphorylation," said Maehama.
The researchers hypothesize that PICT-1 may affect
phosphorylation by activating a kinase or inhibiting a phosphatase.
The identification of PTEN regulators has been a tremendously
difficult problem and this research represents a huge breakthrough.
Maehama explained that this discovery indicates
that cells with impaired PICT-1 function may become cancerous because
of the resulting instability in PTEN. This would represent a new
tumorigenic pathway that is not due to a defective PTEN gene but
rather a loss of PTEN function caused by PICT-1. If this is the case,
then this new type of tumor may be treated with rapamycin or related
drugs that are often used in cancers resulting from PTEN loss of
function. |